Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 496

The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.

Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities

Open access
Davis, Karen D., Aghaeepour, Nima, Ahn, Andrew H., Angst, Martin S., Borsook, David, Brenton, Ashley, Burczynski, Michael E., Crean, Christopher, Edwards, Robert, Gaudilliere, Brice, Hergenroeder, Georgene W., Iadarola, Michael J., Iyengar, Smriti, Jiang, Yunyun, Kong, Jiang-Ti, Mackey, Sean, Saab, Carl Y., Sang, Christine N., Scholz, Joachim, Segerdahl, Marta, Tracey, Irene, Veasley, Christin, Wang, Jing, Wager, Tor D., Wasan, Ajay D., Pelleymounter, Mary Ann·2020·Nature Reviews Neurology

Abstract

Pain medication plays an important role in the treatment of acute and chronic pain conditions, but some drugs, opioids in particular, have been overprescribed or prescribed without adequate safeguards, leading to an alarming rise in medication-related overdose deaths. The NIH Helping to End Addiction Long-term (HEAL) Initiative is a trans-agency effort to provide scientific solutions to stem the opioid crisis. One component of the initiative is to support biomarker discovery and rigorous validation in collaboration with industry leaders to accelerate high-quality clinical research into neurotherapeutics and pain. The use of objective biomarkers and clinical trial end points throughout the drug discovery and development process is crucial to help define pathophysiological subsets of pain, evaluate target engagement of new drugs and predict the analgesic efficacy of new drugs. In 2018, the NIH-led Discovery and Validation of Biomarkers to Develop Non-Addictive Therapeutics for Pain workshop convened scientific leaders from academia, industry, government and patient advocacy groups to discuss progress, challenges, gaps and ideas to facilitate the development of biomarkers and end points for pain. The outcomes of this workshop are outlined in this Consensus Statement. In 2018, the Discovery and Validation of Biomarkers to Develop Non-Addictive Therapeutics for Pain workshop convened to discuss strategies to facilitate the development of biomarkers and end points for pain. The outcomes of this workshop are outlined in this Consensus Statement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41582-020-0362-2

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 228 references

Cited by

See all 496

Metadata

Authors
Davis, K. D., Aghaeepour, N., Ahn, A. H., Angst, M. S., Borsook, D., Brenton, A., Burczynski, M. E., Crean, C., Edwards, R., Gaudilliere, B., Hergenroeder, G. W., Iadarola, M. J., Iyengar, S., Jiang, Y., Kong, J.-T., Mackey, S., Saab, C. Y., Sang, C. N., Scholz, J., Segerdahl, M., Tracey, I., Veasley, C., Wang, J., Wager, T. D., Wasan, A. D., & Pelleymounter, M. A.
Venue
Nature Reviews Neurology
Published
2020-06-15
Volume
16
Issue
7
Pages
381-400
ISSN
  • 1759-4758 (ISSN-L)
  • 1759-4766
OpenAlex
W3035623431
Cited by
496
References
228
FWCI
9.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. https://app.cochat.ai/papers/10.1038/s41582-020-0362-2
The paper
Davis, K. D., Aghaeepour, N., Ahn, A. H., Angst, M. S., Borsook, D., Brenton, A., Burczynski, M. E., Crean, C., Edwards, R., Gaudilliere, B., Hergenroeder, G. W., Iadarola, M. J., Iyengar, S., Jiang, Y., Kong, J.-T., Mackey, S., Saab, C. Y., Sang, C. N., Scholz, J., . . . Pelleymounter, M. A. (2020). Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nature Reviews Neurology. https://doi.org/10.1038/s41582-020-0362-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.